Leerink Partners Report Names Carterra a Core Enabler of the $7B 'Lab-in-the-Loop' Antibody Discovery Market

Carterra’s high-throughput SPR platforms are identified by Leerink Partners as a core enabler of the $7B “Lab-in-the-Loop” antibody discovery market, emphasizing the central role of binding affinity measurement in AI-driven biologics workflows.

Leerink’s competitive landscape analysis names Carterra as a primary supplier of binding affinity infrastructure, highlighting the growing demand for Carterra’s technology in large-scale AI discovery programs.

The report “Lab-in-the-Loop:
AI Rewires Antibody Discovery, Unlocking a $7B LST Opportunity” estimates that wet lab data needs will increase rather than decrease as AI permeates drug discovery, with Carterra platforms integral to generating the antibody binding data sets required by AI-driven discovery programs.